Pirarubicin Hydrochloride
(Synonyms: 盐酸吡柔比星; THP Hydrochloride) 目录号 : GC36928
An anthracycline antitumor antibiotic
Cas No.:95343-20-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Pirarubicin is an anthracycline that has anticancer activity.1 It interacts with topoisomerase II to inhibit DNA replication. Pirarubicin inhibits the growth of human HeLa and C33A cervical, as well as T-24 bladder cancer cells (IC50s = 29, 52, and 36 ng/ml, respectively).2 It inhibits the growth of human Huh7 and MHCC97H liver cancer cells (IC50s = 0.159 and 0.374 μM, respectively).3 Pirarubicin also inhibits the growth of M5076 mouse ovarian cancer cells in vitro (IC50 = 0.366 μM) and in vivo in a mouse allograft model when administered at a dose of 2 mg/kg for four days.4
1.Monneret, C.Recent developments in the field of antitumour anthracyclinesEur. J. Med. Chem.36(6)483-493(2001) 2.Tsuchiya, K.S., Ishii, T., Ikeno, S., et al.Inhibition of anchorage-independent growth of tumor cells by IT-62-B, a new anthracyclineJ. Antibiot. (Tokyo)50(10)853-859(1997) 3.Huang, H., Chen, T., Zhou, Y., et al.RIPK1 inhibition enhances pirarubicin cytotoxic efficacy through AKT-P21-dependent pathway in hepatocellular carcinomaInt. J. Med. Sci.15(14)1648-1657(2018) 4.Sugiyama, T., Sadzuka, Y., Nagasawa, K., et al.Membrane transport and antitumor activity of pirarubicin, and comparison with those of doxorubicinJpn. J. Cancer Res.90(7)775-780(1999)
Cell experiment: | MTS is used to analyze cell survival. Briefly, cells are plated in 96-well plates in triplicate at 2 × 103 cells per well and cultured in growth medium. Then cells are treated with pirarubicin at different concentrations (2.5 μg/mL, 5 μg/mL, 10 μg/mL) for 24 h. MTS reagent (5 mg/mL) is added and incubated at 37°C for 4 h. The absorbance is monitored at 490 nm using a microplate reader[3]. |
Animal experiment: | An acute cardiac toxicity model is established by a single dose of 18 mg/kg pirarubicin through the caudal vein injection. Thirty-six rats are randomized equally to six groups: normal control, cardiac injury (THP) model, dexrazoxane (180 mg/kg), low-dose rutin (25 mg/kg), middle-dose rutin (50 mg/kg), and high-dose rutin (100 mg/kg). Rats in the rutin-treated group are administered different doses of rutin and CMC-Na for 7 days by gavage and a single dose of 18 mg/kg pirarubicin through caudal vein injection. Rats in the dexrazoxane-treated group receive sodium carboxymethylcellulose (CMC-Na) by gavage for six days. 40 mg/kg dexrazoxane is then administered to rats by intraperitoneal injection and 18 mg/kg pirarubicin is administered by caudal vein injection on day 7. Rats in the THP model group receive CMC-Na by gavage for seven days, followed by pirarubicin 18 mg/kg through the caudal vein injection on day 7. Rats in the normal control group receive CMC-Na by gavage for seven days, followed by saline through caudal vein injection on day 7[4]. |
References: [1]. Takigawa N, et al. Cytotoxic effect of topoisomerase II inhibitors against adriamycin- and etoposide-resistant small cell lung cancer sublines. Gan To Kagaku Ryoho. 1993 May;20(7):929-35. | |
| Cas No. | 95343-20-7 | SDF | |
| 别名 | 盐酸吡柔比星; THP Hydrochloride | ||
| Canonical SMILES | O=C1C2=C(C=CC=C2OC)C(C3=C(O)C4=C([C@@H](O[C@@]5([H])C[C@H](N)[C@H](O[C@@]6([H])OCCCC6)[C@H](C)O5)C[C@@](C(CO)=O)(O)C4)C(O)=C31)=O.Cl | ||
| 分子式 | C32H38ClNO12 | 分子量 | 664.1 |
| 溶解度 | DMSO: 20.83 mg/mL (31.37 mM); Water: < 0.1 mg/mL (insoluble) | 储存条件 | 4°C, protect from light |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.5058 mL | 7.529 mL | 15.058 mL |
| 5 mM | 0.3012 mL | 1.5058 mL | 3.0116 mL |
| 10 mM | 0.1506 mL | 0.7529 mL | 1.5058 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet